Eloxx Pharmaceuticals
eloxxpharma.com
Actively hiring
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Eloxx Pharmaceuticals stock reports an Alport trial milestone
Eloxx Pharmaceuticals stock reached a Phase 2b milestone after two patients entered the EXACT study on September 11, 2026. Initial data are due in mid-2027.
Read more
Report
Eloxx Pharmaceuticals stock falls 1.49 percent as trial focus grows
Eloxx Pharmaceuticals stock closed at USD 17.19 on September 21, 2026, down 1.49 percent. Its Phase 2b study began dosing in September.
Read more
Report
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
/PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney...
Read more
Report
Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL)
Detailed price information for Eloxx Pharmaceuticals Inc (ELOX-Q) from The Globe and Mail including charting and trades.
Read more
Report
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the...
Read more
Report
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Read more
Report
Eloxx Pharmaceuticals Announces Key Corporate Accomplishments
Data from Eloxx's proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American...
Read more
Report
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM Platform to Target the Human Ribosome for Therapeutic Benefit
Publication titled
Read more
Report
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM Platform to Target the Human Ribosome for Therapeutic Benefit
--Eloxx Pharmaceuticals, Inc., a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that Cancer Research Communications has published" A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to
Read more
Report
Show more news